Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

WAYNE, N.J. and EMERYVILLE, Calif., June 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.  NExUS evaluated Nexavar versus placebo in combination with two chemotherapeutic agents, gemcitabine and cisplatin.  A positive secondary endpoint of progression-free survival (PFS) was observed in the trial.  The safety and tolerability of the treatment triplet was as expected and did not show any new or unexpected toxicities.  Data from this study are expected to be presented at an upcoming scientific meeting.

Nexavar is currently marketed worldwide for the treatment of hepatocellular carcinoma (HCC), or liver cancer, and advanced renal cell carcinoma (RCC), or kidney cancer.

Enrollment in NExUS commenced in February 2007. In 2008, based on the results seen in a previous Nexavar first-line NSCLC Phase 3 trial, the NExUS study protocol was amended to stop enrolling and treating squamous cell carcinoma patients.  Of the squamous cell patients who were enrolled in the NExUS trial before the amendment, a higher mortality was observed.  This finding was consistent with what was seen in the previous trial.  

Bayer and Onyx will further review the findings of this analysis to det
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
Breaking Medicine Technology:CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the ... announced that Mr. Ofir Paz, InspireMD,s co-founder and chief ... will participate in the Benchmark Company, LLC One-on-One Investor ... Hotel, 424 East Wisconsin Ave., Milwaukee, Wis. The conference ...
... Axcan Intermediate Holdings Inc. announces that it ... the recently completed combination of two specialty pharma companies ... also has a new corporate logo and website (please ... "Our new name, Aptalis, is intended to capture the ...
Cached Medicine Technology:InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 2InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 3The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 2The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 3
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:11/22/2014)... 22, 2014 The topic of B&D ... block retaining walls. The article states that, “While they give ... necessary steps that go into creating this powerful look.” , ... retaining wall is choosing which kind of block matches your ... B&D Rockeries says, “The two main options are concrete and ...
(Date:11/22/2014)... FL (PRWEB) November 22, 2014 ... Innovations are pleased to announce that Ashley Lombardo ... Thanksgiving #PayItForward contest. , Ms. Lombardo entered friend ... Kitchen Innovations. She wrote of how her friend is ... daughters as a single mom. Despite medical bills piling ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... water. , From pollution to hazardous substances in water, ... done to remove these chemicals, especially in water. , ...
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Those air-blown ... germs than conventional paper towels, a new study suggests. ... on the hands of volunteers in order to simulate ... dryers, high-powered "jet-air" dryers or paper towels to dry ... and found higher amounts of germs around both types ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... WEDNESDAY, Aug. 25 (HealthDay News) -- Even prior to ... in four American parents with health insurance reported that their ... medical care their children needed. Parents of kids with ... to say their insurance coverage did not meet their needs, ...
... and promise of using thermal ablation to target and ... of Vascular and Interventional Radiology ,s August supplement, "Thermal ... Goals and Future Technology." "The Journal ... on the development of multiple medical techniques and devices ...
... 11 states will receive more than $6 million in ... on substance abuse and associated problems among U.S. military ... Drug Abuse (NIDA), part of the National Institutes of ... to award grants that will examine substance abuse related ...
... treat metastatic melanoma tumors with a specific genetic signature was successful ... clinical trial. Results of the trial of PLX4032, an inhibitor ... half of all melanomas, appear in the August 26 New ... and is one of the top causes of cancer death in ...
... 25 Vitamin D may be an effective therapy to ... can cause severe complications for patients with cystic fibrosis and ... UPMC, the University of Pittsburgh School of Medicine and Louisiana ... by Jay Kolls, M.D., Ph.D., a lung disease researcher at ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Aug. ... to an inheritable eye disease that affects 5 percent of ... for transplants of the cornea. The genetic disorder, ... the cornea -- the thin, clear membrane that covers the ...
Cached Medicine News:Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 2Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 3Health News:Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 3Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 2Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 3Health News:Vitamin D may treat and prevent allergic reaction to mold in cystic fibrosis patients 2Health News:Study Links Gene to Serious Eye Disease 2
Inquire...
Inquire...
One Piece: Premier Pouches - Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
Inquire...
Medicine Products: